This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Mereo BioPharma Group Faces Class...
Business class action lawsuit

Mereo BioPharma Group Faces Class Action Lawsuit

Analysis based on 50 articles · First reported Jan 29, 2026 · Last updated Mar 08, 2026

Sentiment
-70
Attention
4
Articles
50
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of Mereo BioPharma Group's failed drug trials and the subsequent class action lawsuit, leading to a significant drop in Mereo BioPharma Group's stock price. This event highlights the risks associated with pharmaceutical development and potential legal repercussions for companies.

Biotechnology Pharmaceuticals Legal Services
Event Summary

Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices. This follows a substantial decline in Mereo BioPharma Group's American Depositary Receipt (ADR) price after the company announced that its Phase 3 Orbit and Cosmic studies for UX143 (setrusumab), developed with Ultragenyx, failed to achieve statistical significance. The studies did not meet their primary endpoint of reducing annualized clinical fracture rates, despite showing improved bone mineral density. The initial announcement of the final analysis timeline caused a 42.52% drop, and the subsequent news of study failures led to an 87.7% fall in Mereo BioPharma Group's ADR price.

Key Actions
100 Pomerantz LLP filed class action lawsuit Mereo BioPharma Group
95 Mereo BioPharma Group announced Phase 3 study failure
95 Mereo BioPharma Group announced Phase 3 studies failed to meet primary endpoint
90 Mereo BioPharma Group announced Phase 3 study failures
90 Mereo BioPharma Group ADR price fell significantly
Entities Involved
stock
Mereo BioPharma Group
Mereo BioPharma Group is facing a class action lawsuit due to alleged securities fraud and unlawful business practices. The company's ADR price significantly dropped following negative news regarding its Phase 3 studies for UX143 (setrusumab).
Importance 100 Sentiment -90
priv
Pomerantz LLP
Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group, representing investors who purchased Mereo securities during the Class Period. The firm specializes in corporate, securities, and antitrust class litigation.
Importance 80 Sentiment 70
stock
Ultragenyx
Ultragenyx was a development partner with Mereo BioPharma Group on the UX143 (setrusumab) program. The failure of the Phase 3 studies, while directly impacting Mereo BioPharma Group more severely, also reflects negatively on Ultragenyx's partnership.
Importance 50 Sentiment -20
Relationships
Mereo BioPharma Group related ↔ Pomerantz LLP
Mereo BioPharma Group related ↔ Ultragenyx
Pomerantz LLP related ↔ Mereo BioPharma Group
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.